BACKGROUND: Periconceptional intake of nutrients in addition to folic acid may contribute to neural tube defect (NTD) etiologies; a likely candidate is myo-inositol. We investigated whether maternal periconceptional dietary intake of myo-inositol influenced NTD risk. METHODS: Data were derived from
Dietary myo-inositol therapy in hyperglycemia-induced embryopathy
โ Scribed by Khandelwal, Meena; Reece, E. Albert; Wu, Ying King; Borenstein, Michael
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 108 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0040-3709
No coin nor oath required. For personal study only.
โฆ Synopsis
Dysmorphogenesis in diabetic mothers occurs more frequently than in the general population. This phenomenon is believed to be caused by the teratogenic effects of metabolic fuel mixtures with associated membrane injury and aberrations in the biochemical constituents. The present experiment was designed to determine: 1) if hyperglycemia-induced membrane injury is associated with intracellular and/or extracellular lipid disturbances; 2) if supplemental myoinositol therapy prevents hyperglycemia-induced embryopathy; 3) if a correlation exists between dietary myoinositol, serum and tissue levels of myo-inositol, and conceptus development; and 4) the cellular content of arachidonic acid following myo-inositol supplementation.
Sixty-five female Sprague-Dawley rats were mated, and divided into three groups. One group was nondiabetic normal controls, and two groups had diabetes experimentally induced with streptozotocin. Of the diabetic groups, one received a normal diet, while the other received a myo-inositol-supplemented diet during the period of organogenesis. Blood samples were collected on days 0 and 12 of pregnancy. Embryos and yolk sacs were analyzed for myo-inositol and arachidonic acid levels, using mass spectrochromatography.
Dietary myo-inositol supplementation of diabetic mothers resulted in a significant decrease in the incidence of neural tube defects when compared with diabetics not receiving supplements (9.5 vs. 20.4%; P ฯฝ 0.05). This protective effect was incomplete, based on the incidence observed in the nondiabetic controls (9.5 vs. 3.8%; P ฯฝ 0.05). The myo-inositol embryonic tissue levels in the diabetic group which had been fed a regular diet without supplementation were significantly lower than in the nondiabetic group. Dietary therapy successfully restored myo-inositol levels in the yolk sacs, as suggested by similar tissue levels in diabetics receiving myo-inositol supplementation and normal controls (18.7 ฯฎ 1.3 vs. 19.1 ฯฎ 2.0 ng/mg; P ฯญ ns). Dietary therapy, however, failed to restore myo-inositol levels in the embryos, suggesting hyperglycemia-induced faulty transport of nutrients from the yolk sac to the embryo. No correlation was noted between maternal blood levels of myo-inositol, with or without supplementation, and the clinical outcome. Tissue arachidonic acid levels were markedly reduced in the conceptuses of diabetic
๐ SIMILAR VOLUMES
Brain myo-inositol, an organic osmolyte, is decreased inositol are poorly understood. in cirrhotic patients with hepatic encephalopathy but myo-Inositol is a six-carbon polyol that participates in the appears unchanged in fulminant hepatic failure. An ossynthesis of intracellular signaling compounds